Moteur de recherche d’entreprises européennes
Financement de l’UE (3 432 420 €) : Approches novatrices de la recherche sur l’implantation en santé et maladie Hor 16/07/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Approches novatrices de la recherche sur l’implantation en santé et maladie
Implantation of the embryo in a receptive uterus is critical for mammalian reproduction, yet remains poorly understood. This challenge is particularly significant in human health, as up to two-thirds of human pregnancies are lost due implantation failure. In the agricultural sector, particularly in sustainable milk and meat production, understanding and improving embryo implantation is equally crucial. High peri-implantation mortality rates in livestock lead to lower efficiency, profitability, and environmental sustainability. Much remains unknown about the molecular pathways and regulatory mechanisms of embryo-endometrial interactions in humans and livestock species. For ethical and practical reasons, implantation cannot be adequately studied in vivo in human, and it remains challenging in most animal models. IMPLANTEU is an international community of researchers whose objectives are: 1) To develop a molecular blueprint of human implantation in health and disease; 2) To improve implantation fitness for food production mammals and 3) To develop an advanced toolkit for implantation research. IMPLANTEU provides multi-species, multi-sector and multi-model molecular and system implantation research, integrating complementary expertise in reproductive and stem cells biology, medicine, physiology, ethics and law, and cutting-edge technologies such as stem cell-based embryo models, organoids, machine learning, and organ-on-chip. IMPLANTEU will train 13 doctoral candidates through research, innovation, secondments in academic and industrial environments, horizontal and focused courses, and interactions with stakeholders. The findings generated through IMPLANTEU will contribute to the profound understanding of the embryonic and endometrial contribution to reproductive success, innovations in infertility treatment, animal production efficiency and sustainability, tissue bioengineering, pathogen-host interaction, reproductive toxicology, and stem cell biology.
| Ceva Sante Animale SA | ? |
| Academisch Ziekenhuis Leiden | 274 370 € |
| Biomimx Srl | 259 438 € |
| Euvitro SL | 503 942 € |
| Institut Fuer Molekulare Biotechnologie GmbH | 270 331 € |
| Katholieke Universiteit Leuven | 262 620 € |
| Medizinische Universitat Graz | 540 662 € |
| Universita Degli Studi Di Milano | 259 438 € |
| Universitaetsklinikum Hamburg-Eppendorf | 260 539 € |
| Universitat Politecnica de Valencia | 251 971 € |
| Universiteit Gent | 262 620 € |
| University College Dublin, National University of Ireland, Dublin | 286 488 € |
https://cordis.europa.eu/project/id/101169308
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Ceva Sante Animale SA, Libourne.
